CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 383 enrolled
Drug / intervention
florbetapir F 18 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02016560
NCT02016560Phase 3Completed
CompareCT.gov

An Open Label, Multicenter Study, Evaluating the Safety and Imaging Characteristics of 18F-AV-1451 in Cognitively Healthy Volunteers, Subjects With Mild Cognitive Impairment, and Subjects With Alzheimer's Disease

Avid Radiopharmaceuticals·interventional·Posted Dec 20, 2013·Updated Sep 22, 2020

In Brief

A Phase 3 clinical trial evaluating florbetapir F 18, Flortaucipir F18, and 1 other intervention for Alzheimer's Disease. Completed, enrolled 383 participants across 27 sites.

Detailed Summary

A Phase 2/3 cross-sectional and longitudinal observational study evaluating imaging characteristics of flortaucipir in control subjects and patients with clinically defined MCI and AD dementia (AD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedDec 20, 2013
Enrollment StartDec 1, 2013
Primary CompletionJul 28, 2017
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 12.5 years ago

Interventions

florbetapir F 18drug

Flortaucipir F18drug

Brain PET Scanprocedure

positron emission tomography (PET) scan of the brain